November 6, 2017 / 2:23 PM / a year ago

BUZZ-Neovasc Inc: Gets FDA nod to start Reducer trial

** Canadian medical device maker’s U.S.-listed shares up 14.5 pct at $1.50 premarket

** Receives U.S. FDA approval to start pivotal Reducer system trial to show safety and efficacy of system to treat patients with refractory angina

** Once trial data is completed, data to support application to FDA for approval to begin marketing of Reducer in the United States; reducer was commercially launched in Europe 2 years ago

** Refractory angina is a chest pain caused when coronary arteries deliver an inadequate supply of blood to the heart muscle despite treatment with cardiac drug therapies

** Up to Friday’s close, stock had fallen 24.3 pct YTD (Reporting by Amy Caren Daniel in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below